BioXgen has initiated a Community Investment Round under Regulation Crowdfunding to fund development of its cardiac patch targeting post-operative atrial fibrillation, the most common complication following open-heart surgery. Approximately 50 percent of the 500,000 Americans undergoing open-heart surgery annually develop this arrhythmia within days after surgery, increasing risks of stroke, recurrent atrial fibrillation, kidney failure, and death. The condition costs the U.S. healthcare system approximately $9 billion each year, with no FDA-cleared device currently available for prevention.
The company's cardiac patch is placed directly on the heart surface during surgery, with pre-clinical data published in Circulation showing POAF rates dropping from about 50% to under 5 percent—a tenfold reduction. Over 200 additional patients have been treated with similar results in unpublished data. BioXgen has completed its Q-submission to the FDA, establishing a 510(k) pathway for regulatory clearance. The company targets total development time to clearance at under 18 months if critical funding needs are met, with plans to establish the device as standard of care within 36 to 48 months after approval.
The investment offering is structured as Regulation Crowdfunding and hosted by DealMaker Securities, with investments starting at $500. This approach allows retail investors to participate in a medical device category traditionally reserved for institutional capital. BioXgen maintains a lean operational structure with contracted manufacturing, a growing intellectual property portfolio, and a capitalization table designed to accommodate both community investors and institutional partners.
Company leadership includes Dr. David Skinner as President and CEO, who previously built and exited a medical company at 10x valuation, and Dr. John P. Konhilas as Chief Science Officer, a physiology professor with 30 years of cardiac research experience and 11 patents. The founders will present their investment pitch during a live webinar on Monday, April 7, 2025, at 1:30 PM PT, with registration available at https://dnagency.lpages.co/bioxgen-investor-presentation/. Prospective investors can view the offering details at https://invest.bioxgen.life/, where BioXgen has filed a Form C with the Securities and Exchange Commission, available at https://invest.bioxgen.life/.
For business and technology leaders, BioXgen's approach represents a significant market opportunity in addressing a well-documented clinical gap with substantial economic implications. The company's regulatory strategy through the 510(k) pathway could accelerate time-to-market compared to novel device approvals, while the crowdfunding model democratizes investment in medical innovation. If successful, the cardiac patch could transform post-surgical care protocols and reduce healthcare costs associated with complication management, potentially establishing a new standard in cardiac surgery outcomes.
